NVO - Dicerna Pharmaceuticals: A Solid Pick For 2020
Today, we will be studying why Dicerna Pharmaceuticals (DRNA) is an attractive investment for 2020.
Company overview
Dicerna Pharmaceuticals is a small-cap biopharmaceutical company focused on developing innovative RNAi (RNA interference) therapies. The company is predominantly targeting infectious diseases, rare diseases, and chronic conditions of the liver. The company is also developing RNAi therapies for cardiovascular conditions.
A host of diseases is linked to gene overexpression and the subsequent excessive production of proteins and other substances. Scientists have been deploying a natural biological method, RNAi, for silencing or "turning off" specific genes known